Changes to CADTH’s rapid response service

20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...

Read more →

Upcoming improvements to the CADTH reimbursement review process

5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...

Read more →

CADTH launches post-market drug evaluation program

1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...

Read more →

CADTH launches consultations on proposals to enhance drug review processes

4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...

Read more →

Revised process for cell and gene therapies

21 November 2019 - CADTH has undertaken an internal review and established a novel process for the review of cell and ...

Read more →

Update on revised process for biosimilars

12 December 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and ...

Read more →

Revised process for filing CDR submissions and resubmissions

27 November 2017 - The CADTH Common Drug Review is aligning the process for secure file sharing with the pan-Canadian ...

Read more →

Revised procedure for the CADTH Common Drug Review resubmissions

13 November 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements ...

Read more →

CDR Update — Issue 129

11 October 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission ...

Read more →

Revised procedure for advance notification of pending CDR submissions and resubmissions

28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...

Read more →

Proposed revisions to CADTH’s biosimilar review process

1 August 2017 - Given the type of data required to support biosimilar authorization differs from that required for a biologic ...

Read more →

Proposed revision to the procedure for the CADTH Common Drug Review and the CADTH Therapeutic Review Framework

13 July 2017 - CADTH is inviting stakeholder comments and feedback on proposed revisions to the Procedure for the CADTH Common ...

Read more →

Integrating companion diagnostics into CDR and pCODR reviews

13 June 2017 - In November 2016, CADTH invited stakeholder comments and feedback on a proposed process for the assessment ...

Read more →

Subsequent entry products for non-biological complex drugs

9 June 2017 - In order to reflect the current environment for subsequent entry non-biological complex drugs, CADTH, in consultation ...

Read more →

Expanding CADTH’s drug review processes to include radiopharmaceuticals

17 April 2017 - In collaboration with the participating jurisdictions, CADTH is pleased to announce that it will accept submissions ...

Read more →